1. ER Stress-Activated HSF1 Governs Cancer Cell Resistance to USP7 Inhibitor-Based Chemotherapy through the PERK Pathway
   Chang-Hoon Lim et al, 2024, IJMS CrossRef
2. Al/ZnO nanoparticle as an effective nanocarrier in delivery of lenalidomide anti-multiple myeloma cancer drug
   Licui Zhang et al, 2024, Materials Technology CrossRef
3. Emerging immunologic approaches as cancer anti-angiogenic therapies
   Mohammadreza Azimi et al, 2024, Clin Transl Oncol CrossRef
4. Development and Validation of an Improved HPLC-MS/MS Method for Quantifying Total and Unbound Lenalidomide in Human Plasma
   Suhyun Lee et al, 2024, Pharmaceutics CrossRef
5. Synthesis, Biological Evaluation and in Silico Studies of Novel Urea/Thiourea Derivatives of Lenalidomide
   Fatih Tok et al, 2024, J Biochem & Molecular Tox CrossRef
6. Intercalation of the anticancer drug lenalidomide into montmorillonite for bioavailability improvement: a computational study
   Yumeida V. Meruvia-Rojas et al, 2025, J Mol Model CrossRef
7. Radiation for Multiple Myeloma in the Era of Novel Agents: Indications, Safety, and Dose Selection
   Samuel C. Zhang et al, 2025, Seminars in Radiation Oncology CrossRef
8. Complete Remission of Plasmablastic Lymphoma With Daratumumab and a Mild Regimen of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (Mini-CHOP)
   Samuel Z Davis et al, 2025 CrossRef